<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449382</url>
  </required_header>
  <id_info>
    <org_study_id>CVVH-Na-002</org_study_id>
    <nct_id>NCT02449382</nct_id>
  </id_info>
  <brief_title>Continuous Venovenous Hemofiltration Versus Conventional Treatment for Acute Severe Hypernatremia</brief_title>
  <official_title>To Effect and Safety of Continuous Venovenous Hemofiltration (CVVH) Versus Conventional Treatment for Acute Severe Hypernatremia in Critical Ill Patients: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients with severe hypernatremia who received conventional treatment are often
      undertreated. Continuous venovenous hemofiltration (CVVH) can effectively remove solute or
      water from circulation system. Several case reports demonstrated that CVVH could effectively
      decrease serum sodium concentration of the patients with severe hypernatremia. The use of
      CVVH for acute severe hypernatremia in critically ill patients could improve patient survival
      by effectively decreasing the serum sodium concentration to a normal level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Date collection:

        1. Demographic (gender, age, race, weight, history of drug allergy, complicating diseases,
           drug combination and combination therapy)

        2. CVVH treatment (time, blood vessel, blood flow, replacement fluid flow, the type and
           dose of anticoagulant, limited to the test group)

        3. Vital signs (blood pressure, heart rate, respiratory frequency, body temperature)

        4. Severity of disease

        5. General treatment (Vasoactive drugs, mechanical ventilation, diuretic, steroid hormones)
           6.24 hours input 7.24 hour output

      8.Daily sodium intake 9.Adverse events were confirmed 10.Laboratory date: Routine blood test
      Blood biochemical Blood gas analysis Blood electrolyte Plasma osmotic pressure Urine osmotic
      pressure Plasma osmotic pressure Urinary electrolyte excretion fraction
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day all cause mortality</measure>
    <time_frame>7days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma score changes</measure>
    <time_frame>3 days</time_frame>
    <description>On the third day of the Glasgow Coma score minus baseline of the Glasgow Coma score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score changes</measure>
    <time_frame>3 days</time_frame>
    <description>On the third day of the Sequential Organ Failure Assessment score minus baseline of the Sequential Organ Failure Assessment score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Physiology and Chronic Health Evaluation II score changes</measure>
    <time_frame>3 days</time_frame>
    <description>On the third day of the Acute Physiology and Chronic Health Evaluation II score minus baseline of the Acute Physiology and Chronic Health Evaluation II score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average reduce rate of serum sodium</measure>
    <time_frame>3 days</time_frame>
    <description>The average reduce rate of serum sodium was calculated as following: (serum sodium concentration before treatment (mmol/L) − serum sodium concentration after treatment (mmol/L)) / time after treatment (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour correction of hypernatremia</measure>
    <time_frame>24-hour</time_frame>
    <description>Twenty-four-hour correction of hypernatremia was defined as the reduction of serum sodium concentration to ≤145 mmol/L within 24 hours after the start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypernatremia</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>continuous venovenous hemofiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CVVH was mainly determined by the differences of sodium concentration between serum and replacement fluid. The rate of decline serum sodium could be real-time adjusted using different-sodium-concentration replacement fluid according to the updated serum sodium concentration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of hypernatremia is correction of water deficit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>continuous venovenous hemofiltration</intervention_name>
    <description>If the serum sodium concentration &gt;150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment</description>
    <arm_group_label>continuous venovenous hemofiltration</arm_group_label>
    <other_name>continuous renal replacement therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>standard treatments</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≥18 years

          2. Acute severe hypernatremia(increasing of serum sodium levels from normal levels to
             ≥160 mmol/L within 48 hours)

          3. ICU patients

        Exclusion Criteria:

          1. Hypovolemic hypernatremia fractional excretion of sodium &lt;0.5% and Urea/Creatinine &gt;40
             receiving diuretics: Urea/Creatinine &gt;40, No edema.

          2. Acute kidney injure network III

          3. End-stage renal disease Hemodialysis or peritoneal dialysis

          4. K+&gt;6.5mmol/L The drug is difficult to treat hyperkalemia

          5. Hydrogen ion concentration&lt;7.2 The drug is difficult to treat metabolic acidosis

          6. Acute pulmonary edema

          7. Systolic blood pressure &lt;90 mmHg vasoactive drugs in the treatment of systolic blood
             pressure less than 90 mmHg

          8. The heparin or low molecular allergic patients

          9. HIV positive patients

         10. Pregnant women or lactational pregnancy women

         11. Suspected tuberculosis patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiren Sun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>the First Affiliated Hospital of Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiren Sun, M.D.</last_name>
    <phone>+8602984775193</phone>
    <email>sunshiren@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Feng Ma, M.D.</last_name>
    <phone>+8602984775193</phone>
    <email>28186432@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital of Nephrology</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiren Sun, M.D.</last_name>
      <phone>+8602984775193</phone>
      <email>sunshiren@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Feng Ma, M.D.</last_name>
      <phone>+8602984775193</phone>
      <email>28186432@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shiren Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Huang C, Zhang P, Du R, Li Y, Yu Y, Zhou M, Jing R, Li L, Zheng Y, Wang H, Liu H, He L, Sun S. Treatment of acute hypernatremia in severely burned patients using continuous veno-venous hemofiltration with gradient sodium replacement fluid: a report of nine cases. Intensive Care Med. 2013 Aug;39(8):1495-6. doi: 10.1007/s00134-013-2933-9. Epub 2013 May 8.</citation>
    <PMID>23653182</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Shiren sun</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>continuous venovenous hemofiltration</keyword>
  <keyword>conventional treatment</keyword>
  <keyword>mortality</keyword>
  <keyword>acute severe hypernatremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Hypernatremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

